Israel is the world leader in patents for medical devices, relative to population size, and second in the patenting of biopharm products, including pharmaceuticals and treatments.
Israel is eighth in the number of patents granted in the life-sciences industry, which may be the most amazing statistic of all, given the amount of time and money companies must invest in getting a product or technology tested and patented.
This week, the Israeli biotech industry was having its annual confer...
LifeBond, a biosurgery device company has completed a $20m fund raising, which
was led by Giza Venture Capital and Aurum Ventures. Also participating in the
round were existing investors: Pitango Venture Capital and Mr. Robert Taub,
GlenRock Israel and The Zitelman Group. LifeBond CEO, Ishay Attar said
"LifeBond is marching forward rapidly to provide solutions for major un-met needs
in surgery. We welcome the new investors to the company”
The start-up company LifeBond, which...
Following the big success of ILSI-BioMed Week: some data on Israeli Life Science industry.
The Israeli Life Science Industry is young and growing. Of the existing 702 companies, 56% were founded during the last decade. A closer look reveals that a quarter (173 companies) of the Industry was established in the last five years. Figure 1 depicts the trend and growth experienced by the industry in the 2001-2010, period. 306 companies were established prior to 2001, with the oldest one, Teva Pharm...
President Shimon Peres announced at the 10th ILSI-Biomed Conference 2011 today that he will set up a non-profit organization to support brain research in Israel, which will be headed by Dr. Rafi Gidron. Gidron, a co-founder of Chromatis Networks, which was sold to Lucent for over $4 billion in 2000, is currently involved in volunteer work and invests in cleantech companies through his firm Precede Technologies Ltd.
The aim of the proposed NPO will be to shift the emphasis of research in ...
srael is the world's top investor in R&D as a proportion of GDP in 2011, according to the World Competitiveness Index of 59 countries by Switzerland's IMD Business School. Israel is ranked 17th in competitiveness overall, the same as in 2010.
Israel was also ranked first by IMD in the functioning of central banks.
Hong Kong and the US tied for first place in global competitiveness this year, taking over from Singapore, which fell to third place.
The Federation of Israeli Chambers of C...
In 2010, the Israeli Chief Scientist approved a total of NIS 430 million in various program budgets. The R&D Committee alone considered 338 support applications from 193 companies for life science projects. 265 projects were approved for State assistance.
Statistical reports prepared by the Israeli Chief Scientist office towards the ILSI – Biomed Israel 2011 Week, which will open in Tel Aviv next week (May 23-25, 2011), show that the Chief Scientist helped support life science projects in...
Abbott Diagnostics will be attending Biomed 2011 and is interested in discussions with potential collaborators leading toward the development and commercialization of novel IA/CC biomarkers in all therapeutic areas:
o Evidence of clinical utility
o Well characterized antibody development
o Preferably, a developed ELISA format
o Workable, defendable, global IP position
ResearchPoint Global (RPG) announces its newest member, GCP Clinical Studies Ltd., a leading provider of clinical research services and educational programs in Israel. GCP conducts trials with many of the country’s top medical centers. Its educational program has assisted in establishing high quality standards throughout Israel.
"GCP is delighted and honored to be a part of the RPG organization, since this will offer our local clients the option for conducting professionally well-managed ...
What: The Israel Conference™ encompasses a full day of inspiring global leaders, exciting company CEOs, prominent investors, and internationally recognized industry executives gathering to discuss the vitality and growth of Israel-facing business through a variety of panels on hot industry topics and trends with world-class speakers and high-quality networking. Companies are from high tech, clean tech, medical tech, consumer products, energy, security, and entertainment media technology.
The identity of the buyer of SI Therapies has been revealed: US medical devices giant Boston Scientific (NYSE: BSX), which the past has acquired Israeli companies Remon Medical and Labcoat, and has invested in many Israeli biomed companies and funds.
Aran Research Development & Prototypes has published new details in its financials about the agreement it signed to sell the subsidiary (55 percent), from which it emerges that Boston Scientific paid $5.13 million in cash, and that the purcha...